Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NN5A
|
|||
| Former ID |
DNCL002958
|
|||
| Drug Name |
MK-6096
|
|||
| Synonyms |
FILOREXANT; MK-6096; 1088991-73-4; UNII-E6BTT8VA5Z; MK6096; MK 6096; E6BTT8VA5Z; ((2R,5R)-5-(((5-Fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone; Methanone, [(2R,5R)-5-[[(5-fluoro-2-pyridinyl)oxy]methyl]-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]-; Methanone, ((2R,5R)-5-(((5-fluoro-2-pyridinyl)oxy)methyl)-2-methyl-1-piperidinyl)(5-methyl-2-(2-pyrimidinyl)phenyl)-; Filorexant [USAN:INN]; Filorexant (USAN); Filorexant(mk-6096); MK-6096; Filorexant; GTPL4460
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z] | Phase 2 | [1], [2] | |
| Insomnia [ICD-11: 7A00-7A0Z] | Phase 2 | [1], [2] | ||
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H25FN4O2
|
|||
| Canonical SMILES |
CC1CCC(CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F
|
|||
| InChI |
1S/C24H25FN4O2/c1-16-4-8-20(23-26-10-3-11-27-23)21(12-16)24(30)29-14-18(6-5-17(29)2)15-31-22-9-7-19(25)13-28-22/h3-4,7-13,17-18H,5-6,14-15H2,1-2H3/t17-,18-/m1/s1
|
|||
| InChIKey |
NPFDWHQSDBWQLH-QZTJIDSGSA-N
|
|||
| CAS Number |
CAS 1088991-73-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01021852) Polysomnography Study of MK6096 in Patients With Primary Insomnia (6096-011). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01564459) Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.